Replies to post #269705 on Avid Bioservices Inc (CDMO)

[biopharm]

Choe: March 2014

...a lipid usually found on the inner side of the cell membranes, specifically phosphatidylserine (PS), shifts to the surface, making itself readily available to any passing cellular stranger. This is where the trouble begins.

Soon-Shiong: March 2014

Predictive Protein Pathways
http://nanthealth.com/dna-rna-proteins-cancer-drug/

Lots of info related to Peregrine in that last post, though the main highlight was flipped PS is where the trouble begins, and biomarker of flipped PS is not enough ==>> we need to break this down from DNA to RNA to proteins...

No how many thing that Sunrise subset data will be valuable as I bet they find some BIG PUZZLE PIECES re: protein pathways in blood tests.

I think we need to start finding a way to get this to market and get someone to pay for it. Hmmm, Soon-Shiong is already there...and this article is more important than you may think. Insurers are stepping up, biomarker analysis is almost complete phase I and does flipped PS exist in there ? Oh yes

-----------------------

Molecular Test Integrates DNA, RNA, Quantitative Protein Analysis

June 21, 2016

NantHealth Inc, Culver City, Calif, has launched the Genomic Proteomic Spectrometry Cancer test, or GPS Cancer, a unique, comprehensive molecular test and decision support system that measures the proteins present in a patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

GPS Cancer integrates targeted quantitative proteomics with whole-genome (DNA) and whole-transcriptome (RNA) sequencing, and a knowledge database containing hundreds of oncogenes and approximately 1,500 cellular pathways to identify genomic and proteomic alterations—from DNA to RNA to protein. To inform personalized treatment strategies, the system targets proteins with high clinical relevance to each person’s tumor, providing oncologists with a detailed molecular profile of the patient’s cancer.

The system has the capability to quantify proteins that have known clinical significance relating to activity or resistance to chemotherapy, monoclonal antibody therapy (mAb), hormonal therapy, small molecule targeted therapy, and checkpoint inhibitors. Combined with whole-genome and transcriptomic analysis, the test provides informed clinical decision support, arming the physician with insight into the patient’s response and resistance to particular therapeutics before treatment begins. The information is available within 21 days of receipt of the tissue, thus enabling clinical utility.

Results are available to doctors in an easy-to-read report or accessible through the GPS Cancer Genome Browser, a mobile application available on smartphones. The app enables users to browse the patient’s whole genome down to a single base pair, and provides visual insight into genomic alterations along with relevant data about those alterations.

GPS Cancer testing is conducted in the CLIA-certified and CAP-accredited laboratory of NantOmics, Culver City, Calif, and is an enabler for the Cancer MoonShot 2020 cancer care collaborative.

“The ability to bring next-generation cancer treatments to patients marks a significant milestone in the war against cancer,” says Patrick Soon-Shiong, MD, founder and CEO of NantHealth. “While genomics has undoubtedly advanced our ability to treat cancer, gene panels have only given us a partial picture and only look at a fraction of the genome. We have leapfrogged from genomics to the era of clinically relevant proteomics with this comprehensive integration of DNA, RNA, and quantitative protein analysis in a single molecular test—GPS Cancer.

“Coupled with robust predictive analytics, this 21st century molecular profile offers clinicians and patients a powerful tool in fighting cancer at the point of care and before treatment begins,” Soon-Shiong says.

The test is an enabler for facilitating the goals of the Cancer MoonShot 2020, he adds. “GPS Cancer may accelerate efforts to bring novel combinations of therapeutic agents to cancer patients by providing the molecular fingerprinting foundation necessary to help identify patients eligible for quantitative integrative lifelong trials,” he adds. “These clinical trials, which are at the heart of Cancer MoonShot 2020, are aimed to accelerate the potential of immunotherapy as the new standard of care for cancer patients by harnessing the power of the immune system to fight this disease.”?

GPS Cancer sequences the whole genome of more than 20,000 genes and 3 billion base pairs, and matches them against the patient’s normal DNA, providing oncologists with an expansive view of alterations to inform personalized treatment strategies specific for that patient. GPS Cancer extends from genomics to proteomics not only through analysis of RNA but also provides quantitative proteomics through mass spectrometry to measure the amounts of clinically relevant proteins that are essential for various therapeutics. The clinically relevant information helps oncologists to better understand how patients may potentially respond to chemotherapies, targeted therapies, and immunotherapies.

”At Indiana University Health, we aim to identify innovative therapeutic options for metastatic cancer patients through the use of cutting-edge precision medicine technologies,” says Milan Radovich, PhD, codirector of the Indiana University Health Precision Genomics Program. “GPS Cancer, with its combination of genomic and proteomic profiling has revealed numerous opportunities for treatment, providing actionable results for the majority of our patients.”

In January 2016, Independence Blue Cross became the first major insurer to offer its members reimbursement for GPS Cancer. In May 2016, NantHealth expanded coverage of GPS Cancer to organizations nationwide, including Bank of America, Phoenix Children’s Hospital, and Sanford Health.

http://www.clpmag.com/2016/06/molecular-test-integrates-dna-rna-quantitative-protein-analysis/

Flipped PS is when the trouble begins

March 2014 is when the excitement began

DNA to RNA to predictive protein pathways <> blood test

PS Targeting on the way to $150 Billion+ and now lets make sure all common shares of PPHM maintain their full voting rights

I know I am jumping ahead a bit.... but you read the past couple posts and its all coming down to protein pathways. Hmmm, just wait till they see the predictive protein pathways in Alzheimers!

[Protector]

biopharm, goo article. We know the answer to the research question: How can we block PS :)

I figure that these researchers by know must have found out that the PS receptor that expresses on phagocytes is TIM-4. They will like to hear that in the Hokaido University in Japan because they are the anti-TIM-4 team.

Who at PPHM that reads my posts went to Japan? Maybe someone needs to tell them that there are MANY PS receptors and that JUST binding TIM-4 will not help because the army of phagocytes will keep growing because if PS exposing cells (no matter whether it is due to Apoptosis or to viral/cancer related damage) are NOT engulfed by phagocytes (because they where disabled by, say, TIM-4 so that PS cannot bind them and tell them 'EAT MORE') then the still 'free' PS keeps crying out louder and louder : APOPTOSIS, pls send more garbage trucks (phagocytes) and hence more targets vehicles for the Dengue or West Nile viruses viruses.

To solve the problem you need to bind ALL PS receptors which says : This PS is NOT part of APOPTOSIS, pls send troops first, garbage collection later.

That was indeed the sentence to highlight :)

Infection of cells by dengue or West Nile viruses is markedly enhanced when phagocytes express receptors that recognize and bind PS.

Remember this post with PS receptor variety?


Tim-4 Is Involved in Both the Adhesion and Ingestion Processes of Phagocytosis of Apoptotic Cells.